FDA official logo
GSRS logoPFDA official logo

MIRZOTAMAB CLEZUTOCLAX

UNII:TY49T0B03B
Formula:
Preferred Substance Name:MIRZOTAMAB CLEZUTOCLAX

  • 2229859-12-3
  • ABBV155
  • ABBV-155
  • IMMUNOGLOBULIN G1 (234-ALANINE,235-ALANINE), ANTI-(HUMAN B7 HOMOLOG 3 PROTEIN) (HUMAN MONOCLONAL PR-1651850 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL PR-1651850 .KAPPA.-CHAIN, DIMER, BIS(THIOETHER) WITH 2,6-ANHYDRO-8-(2-(((((2-((3-((4-(6-(8-((2-BENZOTHIAZOLYLAMINO)CARBONYL)-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)-2-CARBOXY-3-PYRIDINYL)-5-METHYL-1H-PYRAZOL-1-YL)METHYL)-5,7-DIMETHYLTRICYCLO(3.3.1.13,7)DEC-1-YL)OXY)ETHYL)((3S)-3,4-DIHYDROXYBUTYL)AMINO)CARBONYL)OXY)METHYL)-5-((N-(2-((3S,5S)-3-((3-CARBOXY-2-MERCAPTO-1-OXOPROPYL)AMINO)-2-OXO-5-((2-SULFOETHOXY)METHYL)-1-PYRROLIDINYL)ACETYL)-L-VALYL-L-ALANYL)AMINO)PHENYL)-7,8-DIDEOXY-L-GLYCERO-L-GULO-OCTONIC ACID
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD276 ANTIGEN (4IG-B7-H3, B7 HOMOLOG 3, COSTIMULATORY MOLECULE)), MONOCLONAL ANTIBODY, CONJUGATED WITH CLEZUTOCLAX, AN INHIBITOR OF BCL-2-LIKE PROTEIN 1 (BCL2-L-1, APOPTOSIS REGULATOR BCL-X); .GAMMA.1 HEAVY CHAIN CHIMERIC(1-446) (VH (MUS MUSCULUS IGHV3-1*02 (87%) (IGHD)-IGHJ2*01 (87%)/HOMO SAPIENS IGHV4-38-2*01 (84%) (IGHD)-IGHJ4*01 (87%)) (9.7.9) (1-116)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(213))),CH2(L4 >A(233),L5 >A(234))) (117-446)) (219-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN HUMANIZED(1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (82%) IGKJ2*02) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (225-225'':228-228'')-BISDISULFIDE, PRODUCED IN CHO CELLS, GLYCOFORM ALFA; CONJUGATED,ON AN AVERAGE OF 2 CYSTEINYL, WITH CLEZUTOCLAX, COMPRISING A CLEAVABLE DIPEPTIDE (VALINE-ALANINE) LINKER
  • MIRZOTAMAB CLEZUTOCLAX [INN]
  • MIRZOTAMAB CLEZUTOCLAX [USAN]
  • MIRZOTAMAB CLEZUTOCLAX [WHO-DD]




UNII - TY49T0B03B | UNII Search Service